Moonshots

Peter Diamandis × Salim Ismail × Dave Blundin × Dr. Alexander Wissner-Gross

Dario Amodei proposes slowing frontier releases through employee-level third-party evaluators, lab coordination, and international bioweapons cooperation, while Alex Wissner-Gross calls the campaign a possible “safety cartel.”Anthropic reports biological-weapons cases and says it can no longer confidently assure models remain below the dangerous threshold, strengthening the case for mutual API testing while leaving cartel-like coordination unresolved.

Peter Diamandis × Salim Ismail × Dave Blundin × Dr. Alexander Wissner-Gross

OpenClaw’s breakthrough is autonomous, continuous agents that combine frontier or local open-weight models with memory, tools, and native messaging interfaces rather than a new foundation model.That distribution unlock also creates the gating risk: agents with access to email, payments, and open ports could cause industrial accidents, while compute-equity deals and falling intelligence costs accelerate infrastructure demand before personhood and control are resolved.

Peter Diamandis × Eric Schmidt × Dave Blundin

Eric Schmidt expects America to retain the top-end AGI lead while China embeds AI everywhere and dominates inexpensive physical systems, including Unitree’s $6,000 R1; electricity, not chips, may become America’s binding constraint.Falling compute costs and open Chinese models weaken static controls and could establish global standards through price, while biology remains the catalyst most likely to force coordinated policy and a major test of startup defensibility.

Ben Horowitz × Peter Diamandis × Salim Ismail

Washington’s shift from “complete war with the industry” to “aggressive pro-tech” could release blocked exits and revive crypto development, but Stargate’s quoted $500 million and $500 billion figures remain unclear while energy constrains AI infrastructure.DeepSeek’s roughly 100-times-lower token cost and AI-driven drug design strengthen the case for decentralized innovation, yet founders still need operational discipline, physical trials, and supply chains that remain overwhelmingly Chinese.